CN112312910A - 人整合素α4β7拮抗剂 - Google Patents

人整合素α4β7拮抗剂 Download PDF

Info

Publication number
CN112312910A
CN112312910A CN201980033206.5A CN201980033206A CN112312910A CN 112312910 A CN112312910 A CN 112312910A CN 201980033206 A CN201980033206 A CN 201980033206A CN 112312910 A CN112312910 A CN 112312910A
Authority
CN
China
Prior art keywords
compound
methyl
group
alkyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980033206.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·G·伯萨维奇
D·M·特罗亚斯特
B·A·哈里森
B·S·利帕
B·N·罗杰斯
K·D·康策
A·I·格拉休托
T·戴
林富扬
K·N·哈恩
M·A·斯文森
金丙澯
钟诚
A·A·卢戈夫斯科伊
B·索萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Murphy Medical Co ltd
Original Assignee
Murphy Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Murphy Medical Co ltd filed Critical Murphy Medical Co ltd
Publication of CN112312910A publication Critical patent/CN112312910A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
CN201980033206.5A 2018-04-12 2019-04-12 人整合素α4β7拮抗剂 Pending CN112312910A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656742P 2018-04-12 2018-04-12
US62/656742 2018-04-12
PCT/US2019/027141 WO2019200202A1 (en) 2018-04-12 2019-04-12 Antagonists of human integrin (alpha4)(beta7)

Publications (1)

Publication Number Publication Date
CN112312910A true CN112312910A (zh) 2021-02-02

Family

ID=68161020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033206.5A Pending CN112312910A (zh) 2018-04-12 2019-04-12 人整合素α4β7拮抗剂

Country Status (8)

Country Link
US (4) US10759756B2 (https=)
EP (1) EP3773573B1 (https=)
JP (2) JP7365358B2 (https=)
CN (1) CN112312910A (https=)
AR (1) AR114489A1 (https=)
MA (1) MA52249A (https=)
TW (2) TW202528300A (https=)
WO (1) WO2019200202A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115087444A (zh) * 2019-10-16 2022-09-20 莫菲克医疗股份有限公司 抑制人整联蛋白α4β7
WO2023125182A1 (zh) * 2021-12-27 2023-07-06 海思科医药集团股份有限公司 一种丙酸衍生物及其在医药上的应用
WO2024051819A1 (zh) * 2022-09-09 2024-03-14 西藏海思科制药有限公司 一种丙酸衍生物及其在医药上的应用
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7365358B2 (ja) * 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
IL302906A (en) * 2020-11-20 2023-07-01 Denali Therapeutics Inc Compounds, compositions, and methods
KR20250120367A (ko) * 2022-12-22 2025-08-08 신테라, 인크. 알파4 베타7 인테그린 안타고니스트 및 이의 용도
JP2026506997A (ja) * 2023-02-21 2026-02-27 シーフォーエックス・ディスカバリー・リミテッド 大環状アルファ４ベータ７インテグリン阻害剤
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TW202515852A (zh) * 2023-09-15 2025-04-16 美商莫菲克醫療股份有限公司 抑制人類整合素α４β７

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134696A (zh) * 1993-11-15 1996-10-30 赫彻斯特股份公司 取代的5-元杂环，它们的制备方法及用途
CN1202893A (zh) * 1995-05-31 1998-12-23 杜邦麦克药品公司 新的异噁唑啉和异噁唑纤维蛋白原受体拮抗剂
CN1225360A (zh) * 1997-11-19 1999-08-11 德国赫彻斯特马里奥罗塞尔有限公司 取代的咪唑烷衍生物,其制备、用途以及含有它们的药物制剂
WO2000000481A1 (en) * 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US20020183374A1 (en) * 2001-03-10 2002-12-05 Volkmar Wehner Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients
US20030199692A1 (en) * 1999-05-07 2003-10-23 Biediger Ronald J. Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6667334B1 (en) * 1998-05-14 2003-12-23 Aventis Pharma Deutschland Gmbh Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
US6953798B1 (en) * 1998-11-30 2005-10-11 Celltech R&D Limited β-alanine derivates

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2159450C (en) * 1993-03-31 2002-01-08 Norman Anthony Abood 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
BR9408137A (pt) 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
EP0932615A1 (en) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
BR0010349B1 (pt) * 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
CA2385882C (en) 1999-09-24 2009-11-24 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
AU2006254772B2 (en) 2005-06-09 2011-06-02 Ucb Pharma S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
EP3412309A1 (en) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Methods of administering beta7 integrin antagonists
EP2903691B1 (en) 2012-10-05 2019-05-22 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
WO2016011940A1 (zh) 2014-07-25 2016-01-28 江苏恒瑞医药股份有限公司 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用
KR20170120601A (ko) 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2021076890A1 (en) 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134696A (zh) * 1993-11-15 1996-10-30 赫彻斯特股份公司 取代的5-元杂环，它们的制备方法及用途
CN1202893A (zh) * 1995-05-31 1998-12-23 杜邦麦克药品公司 新的异噁唑啉和异噁唑纤维蛋白原受体拮抗剂
CN1225360A (zh) * 1997-11-19 1999-08-11 德国赫彻斯特马里奥罗塞尔有限公司 取代的咪唑烷衍生物,其制备、用途以及含有它们的药物制剂
US6667334B1 (en) * 1998-05-14 2003-12-23 Aventis Pharma Deutschland Gmbh Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
WO2000000481A1 (en) * 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6953798B1 (en) * 1998-11-30 2005-10-11 Celltech R&D Limited β-alanine derivates
US20030199692A1 (en) * 1999-05-07 2003-10-23 Biediger Ronald J. Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US20020183374A1 (en) * 2001-03-10 2002-12-05 Volkmar Wehner Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115087444A (zh) * 2019-10-16 2022-09-20 莫菲克医疗股份有限公司 抑制人整联蛋白α4β7
CN115087444B (zh) * 2019-10-16 2024-09-17 莫菲克医疗股份有限公司 抑制人整联蛋白α4β7
WO2023125182A1 (zh) * 2021-12-27 2023-07-06 海思科医药集团股份有限公司 一种丙酸衍生物及其在医药上的应用
WO2024051819A1 (zh) * 2022-09-09 2024-03-14 西藏海思科制药有限公司 一种丙酸衍生物及其在医药上的应用
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用

Also Published As

Publication number Publication date
JP7700193B2 (ja) 2025-06-30
MA52249A (fr) 2021-05-05
US20240294475A1 (en) 2024-09-05
JP2024001201A (ja) 2024-01-09
US20220340529A1 (en) 2022-10-27
AR114489A1 (es) 2020-09-09
TW202528300A (zh) 2025-07-16
US20200385352A1 (en) 2020-12-10
US12221416B2 (en) 2025-02-11
TWI856956B (zh) 2024-10-01
JP7365358B2 (ja) 2023-10-19
WO2019200202A1 (en) 2019-10-17
EP3773573A4 (en) 2022-04-06
US11174228B2 (en) 2021-11-16
EP3773573B1 (en) 2026-03-18
EP3773573A1 (en) 2021-02-17
TW202003466A (zh) 2020-01-16
US10759756B2 (en) 2020-09-01
JP2021531234A (ja) 2021-11-18
US20190315692A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
CN112312910A (zh) 人整合素α4β7拮抗剂
EP3483142B1 (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN108283000B (zh) γ-羟基丁酸的前药及其组合物和用途
CN108929263B (zh) 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途
CN111212835A (zh) 用于雄激素受体的靶向降解的化合物和方法
CN109790149B (zh) 苯氧基三唑类化合物
TW201726606A (zh) 作為免疫調節劑之化合物
CN113444063A (zh) 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途
WO2024088408A1 (zh) 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
ES2991287T3 (es) Compuestos derivados del 1,3,4-oxadiazol como inhibidor de la histona 6 desacetilasa, y la composición farmacéutica que comprende los mismos
CN111356699A (zh) 活性氧清除剂的制备及用途
CN109111451A (zh) 二氢嘧啶类化合物及其在药物中的应用
JP7051009B2 (ja) アミノペプチダーゼａ阻害剤及びそれを含む医薬組成物
KR20200125967A (ko) 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도
WO2024175026A1 (zh) 含氮杂环类化合物及其医药用途
KR20250030474A (ko) 화합물, 조성물 및 이의 사용 방법
HK40045069A (en) Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
HK40001145B (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
HK40001145A (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
HK1257965B (en) Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
HK40005681A (en) Phenoxytriazoles
HK1130050A (en) Novel, cyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination